The
European Medicines Agency (EMA) has recommended Holoclar, the first advanced
therapy medicinal product (ATMP) containing stem cells, for approval in the
European Union (EU). Holoclar is a treatment for moderate to severe limbal stem
cell deficiency (LSCD) due to physical or chemical burns to the eye(s) in
adults. It is the first medicine recommended for LSCD, a rare eye condition
that can result in blindness.
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources